▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Cory Renauer

TMFang4apples

Cory Renauer is a contributing Healthcare Analyst at The Motley Fool, covering publicly traded companies across pharmaceuticals, biotechnology, and medical devices. Prior to The Motley Fool, Cory was an educator in Thailand and a laboratory technician for the American Red Cross. He holds a B.S. in Biology from Oakland University. Fun fact: Cory has a collection of novelty socks featuring famous stock market symbols and iconic investor quotes.

Recent Articles by Cory Renauer

hurdle-businessman-getty

Jun 3, 2020 by Cory Renauer

Eli Lilly Leaps Past Regeneron's COVID-19 Treatment Candidate

In the race to develop an effective new coronavirus treatment, one of the West Coast's premier biotechnology companies just got lapped by the oldest pharmaceutical giant in the Midwest.

physician-icu-clipboard-getty

Jun 1, 2020 by Cory Renauer

Eli Lilly Is Already Testing a COVID-19 Antibody Treatment in Humans

The big pharma's collaboration with AbCellera to create a coronavirus treatment is sprinting forward.

rocket-on-launch-pad

May 29, 2020 by Cory Renauer

Here's Why Adaptimmune Therapeutics Is Rocketing Higher Today

Positive results from a handful of patients treated have bolstered confidence in the company's cell-based approach to cancer treatment.

doctor-healthcare-stock-getty

May 29, 2020 by Cory Renauer

AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead

Recently reported clinical trial data on Tagrisso shows that it lowers the risk of disease recurrence or death by 83% for some classes of lung cancer patients.

Physician-examining-brain-scans-getty

May 28, 2020 by Cory Renauer

Eli Lilly Earns Landmark Approval for Alzheimer's Disease Imaging Agent

It's not a treatment for this memory-robbing dementia, but it could help Lilly and its peers find one.

pharma-manufacturing-clean-room-getty

May 28, 2020 by Cory Renauer

Novartis to Manufacture Mass General's Coronavirus Vaccine Candidate

A subsidiary of the pharmaceutical giant will soon ramp up production of the nonprofit hospital's SARS-CoV-2 vaccine candidate, which has yet to enter human clinical trials.

coins-falling-through-his-hands-getty

May 27, 2020 by Cory Renauer

Here's Why Arcus Biosciences Is Losing Ground Today

Investors expecting a buyout offer were disappointed by the collaboration agreement Gilead Sciences offered.

covid-19-vaccine-coronavirus-getty

May 27, 2020 by Cory Renauer

Novavax Makes a $167 Million Purchase to Boost Its Coronavirus Vaccine Production Capacity

After acquiring a Czech company, the clinical-stage biotech will be able to churn out more than 1 billion doses of its SARS-CoV-2 vaccine candidate next year -- if it works.

shaking-hands-in-suits-getty

May 26, 2020 by Cory Renauer

At Last, Merck Is Diving Into Coronavirus Vaccine and Antiviral Development

The big pharma has finally joined its peers, launching multiple projects aimed at stopping COVID-19 in its tracks.

folded-1-bill-shaped-like-an-arrow-pointing-up

May 26, 2020 by Cory Renauer

Here's Why argenx Stock Is Soaring Today

Positive pivotal trial results are giving investors a reason to cheer.

biotech-microscope-getty

May 24, 2020 by Cory Renauer

Oxford Professor Lowers Coronavirus Vaccine's Odds of Meeting September Deadline

Oxford University's coronavirus vaccine project leader isn't as enthusiastic as you want him to be.

physician-icu-clipboard-getty

May 23, 2020 by Cory Renauer

Mixed Results for Gilead Sciences' COVID-19 Treatment

Remdesivir helped patients recover faster, but the experimental coronavirus treatment didn't lower patients' risk of death.

fda-approval-drugs-getty

Jun 22, 2020 by Cory Renauer

FDA Approves Generic Version of Amarin's Blockbuster Fish Oil Capsules

The arrival of a generic version of Vascepa will be bad news for the company.

GettyImages-1209275440

May 21, 2020 by Cory Renauer

CVS Health Expands COVID-19 Rapid Testing in Minority Neighborhoods

The retail and pharmaceutical services behemoth will focus on communities with large populations of minorities hit hardest by the pandemic.

clinical-trial-theme-getty

May 21, 2020 by Cory Renauer

U.S. Seals Deal with AstraZeneca for 300 Million Doses of Potential Coronavirus Vaccine

By pledging up to $1.2 billion in assistance, the Department of Health and Human Services has ensured its access to a large supply of the ChAdOx1 nCoV-19 vaccine -- assuming it works.

confused-businessman-getty

May 21, 2020 by Cory Renauer

Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib Results

In a phase 2b/3 study in ulcerative colitis, the drug candidate met its goals, but with results that didn't appear better than those of a potential competitor.

scientist-reading-something-complicated-getty

May 20, 2020 by Cory Renauer

FDA Approves New Prostate Cancer Treatment From AstraZeneca and Merck

Lynparza could generate blockbuster sales as a new treatment option that isn't hormone-based.

pipette-money-drop-getty

May 20, 2020 by Cory Renauer

Will Co-Diagnostics Stock Go to $30?

For the molecular diagnostics company to earn such a big boost in its valuation, sales of its COVID-19 test will need to grow at an ambitious rate.

healthcare-provider-helping-a-patient-stand-getty

May 21, 2020 by Cory Renauer

Johnson & Johnson's Oncology Team Posts Promising Cancer Trial Results

A double-sided antibody with blockbuster potential shrank tumors for relapsed multiple myeloma patients who have run out of treatment options.

benjamin-hiding-under-big-pills-getty

May 19, 2020 by Cory Renauer

Is Moderna Stock Really Headed to $112?

Wall Street analysts are cranking up their price targets on the biotech in response to early clinical trial results for its coronavirus vaccine candidate.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services